Akari Therapeutics (AKTX) Is Advancing the Next Generation of Antibody Drug Conjugates Through Novel Payload Innovation

This is sponsored content. Barchart is not endorsing the websites or products set forth below.

Akari Therapeutics (NASDAQ: AKTX) is developing a new generation of antibody-drug conjugates (ADCs), one of the fastest-growing areas in oncology. ADCs are designed to deliver highly potent cancer-killing agents directly to tumor cells while minimizing damage to healthy tissue, an approach that has fueled more than $75 billion in pharmaceutical transactions over the past three years.

However, approximately 95% of ADCs in development today rely on one of two established payload classes, topoisomerase I inhibitors or microtubule inhibitors. Despite the rapid growth of the ADC market, innovation in payload technology has remained relatively limited. Akari is developing a novel payload class designed to attack cancer through a fundamentally different biological mechanism, an approach that has generated growing scientific and industry interest.
As the ADC Market Expands, Repeated Use of the Same Payload Classes Is Emerging as an Important Clinical Challenge

The payload is the cancer-killing component of an ADC. While existing payload classes have driven much of the success of the ADC market, their widespread use is creating new challenges in treatment sequencing, or determining which therapies are likely to remain effective after a patient has already received an ADC using a similar payload.

As patients receive ADCs earlier in their treatment journey, some tumors may become less responsive to subsequent therapies that rely on the same payload class. This can reduce treatment options over time and highlights the need for novel payload mechanisms that attack cancer through different biological pathways. Akari is developing its proprietary PH1 payload to help address this emerging challenge.

Akari Is Developing a Novel Payload Class for the Next Generation of ADCs

Akari's proprietary payload, PH1, was designed to attack cancer through an entirely different biological mechanism than conventional ADC payloads. Rather than targeting cell division or DNA damage repair mechanisms (microtubule and topoisomerase inhibitors respectively), the PH1 payload modulates RNA splicing, a fundamental cellular process that cancer cells rely on to grow and survive. This differentiated mechanism is designed to provide an alternative to the payload classes that currently dominate the ADC landscape and may offer physicians an additional option as they navigate the challenges associated with repeated exposure to conventional ADC payloads. Because the topoisomerase I and microtubule inhibitor payloads used in most ADCs are substrates for the multidrug-resistance efflux transporters implicated in ADC-to-ADC cross-resistance, PH1's distinct chemical class is designed to retain activity in tumors and patients that have progressed on prior ADC payloads.

Beyond its distinct mechanism of action, PH1 has also demonstrated the potential to activate the immune system in preclinical studies, functioning as both a cytotoxic and an immune-activating payload. This dual activity of PH1 ADCs, direct tumor cell killing alongside engagement of innate and adaptive anti-tumor immunity, has shown in preclinical models to complement PH1's direct anti-tumor effects and demonstrate superior responses to those achieved through conventional, ADC payloads, either as single agent or when used in combination with checkpoint inhibitors.

Akari's lead ADC candidate, AKTX-101, combines the PH1 payload with an antibody targeting Trop2, a receptor broadly expressed across multiple solid tumor types.

Across multiple preclinical studies, AKTX-101 has demonstrated:

• Superior anti-tumor activity and prolonged survival compared with ADCs utilizing conventional payloads
• Synergistic activity when combined with checkpoint inhibitors
• A differentiated safety profile, that does not show side effects typically seen with traditional ADC payloads such as such as neutropenia, interstitial lung disease and neuropathies. Broad activity even across tumors driven by the most aggressive oncogenic drivers such as KRAS, BRAF, FGFR3 fusions, SMARCA4, and other clinically relevant oncogenic drivers

This unique mechanism of action and impact on a wide range of cancer cells was further highlighted at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where Akari presented preclinical data demonstrating synergistic activity between AKTX-101 and a KRAS inhibitor in KRAS-mutated pancreatic cancer model, one of the most difficult cancers to treat and an area of significant unmet medical need. Importantly, this synergistic activity of AKTX-101 with a KRAS inhibitor was not seen with other established Trop2 ADCs that use topoisomerase inhibitor payloads, highlighting the unique effects of the PH1 payload against KRAS mutant cancer cells.

"The ADC field has advanced rapidly over the past several years, but innovation in payload technology has remained relatively limited," said Abizer Gaslightwala, President and CEO of Akari Therapeutics. “We believe PH1 represents a differentiated payload class with the potential to expand the utility of ADCs by targeting cancer through an entirely different biological mechanism. The preclinical data generated to date continue to strengthen our confidence in AKTX-101 as we advance the program toward the clinic.”
IND-Enabling Studies Are Underway as Akari Advances Toward a Phase 1 Trial

IND-enabling studies for AKTX-101 are underway as Akari advances its lead program toward a planned Phase 1 first-in-human clinical trial in mid-2027. The upcoming study is expected to represent the first clinical evaluation of the Company's proprietary PH1 payload platform and an important step in validating its differentiated RNA splicing approach in patients.

The Bull Case for AKTX

As the ADC market continues to mature, innovation is increasingly shifting beyond antibodies and toward novel payload classes designed to address the limitations of existing therapies. Recent industry deal activity suggests large pharmaceutical companies are placing growing strategic value on differentiated payload technologies. 

• Industry interest in novel payloads is accelerating.
   In July 2026, Novartis agreed to acquire Myricx Bio for up to $1.5 billion—including approximately $1.1 billion in cash upfront, to gain access to its novel preclinical N-myristoyltransferase inhibitor (NMTi) payload platform, citing the need for new payload mechanisms to address resistance associated with conventional ADC payload classes. This followed Gilead's multibillion-dollar acquisition of Tubulis and Eli Lilly's acquisition of CrossBridge Bio earlier in 2026, three separate 2026 deals in which large pharmaceutical companies paid a premium for differentiated ADC platforms while still at preclinical and early clinical development stages.
• Akari is pursuing a similarly differentiated strategy.
   PH1 is designed to target cancer by disrupting RNA splicing, representing a novel payload class that differs from the topoisomerase I and microtubule inhibitor payloads that dominate today's ADC landscape.
• The platform has demonstrated encouraging preclinical activity that is differentiated as compared to current ADCs using traditional payloads.
• AKTX-101 has shown superior anti-tumor activity, prolonged survival compared to traditional ADC therapies, and strong combination potential with other cancer therapeutics, supporting continued advancement toward the clinic.
• Multiple value-creation catalysts remain ahead.
   IND-enabling studies are underway, with a planned first-in-human Phase 1 trial initiation in mid-2027. Akari's partnership with WuXi XDC, a global leader in ADC manufacturing and development. Akari is leveraging the best players in the industry to quickly and efficiently advance its novel ADC platform into clinical trials.
• Increasing Excitement in PH1 Payload from Oncology Experts: 
   Akari continues to expand its Scientific Advisory Board of expert advisors to assist in the development of AKTX-101 and the PH1 payload. The recent appointment of Dr. Patricia LoRusso to its Scientific Advisory Board highlights the growing excitement about this novel PH1 payload. Dr. Lo Russo isa past president of the American Association for Cancer Research and has played a key role in the early development of several ADC therapies and will provide expert advice to help Akari demonstrate the potential of its AKTX-101 asset in early clinical trials.
• Akari valuation appears disconnected from recent ADC M&A.
   Recent preclinical, novel-payload ADC platforms have commanded roughly $300M to $5B in acquisition value in 2026 alone. As a public, preclinical novel-payload ADC company pursuing the same thesis, Akari currently trades at a small fraction of those comparables.

The growing pharma oncology focus on novel ADC payload classes underscores the strategic importance of differentiated platform technologies. With its novel ADC payload PH1, Akari is advancing AKTX-101 toward clinical development and multiple value-creating milestones ahead. Akari is positioned to lead in what could be the next wave of innovation across the rapidly expanding ADC market.

The above is sponsored content. Barchart was paid up to twenty seven thousand four hundred ninety eight dollars for placement and promotion of the content on this site and other forms of public distribution covering the period of July 2026.  For more information please view the Barchart Disclosure Policy here.